Can you provide the upcoming earnings date for Thiogenesis Therapeutics Corp?
Thiogenesis Therapeutics Corp (TTI.CA) will report earnings on 2026-04-23.
Thiogenesis Therapeutics Corp (TTI.CA) Forecast, Price Target & Analyst Ratings
TSX-V:TTI
Current stock price
0.49 CAD
+0.02 (+3.16%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Thiogenesis Therapeutics Corp (TTI.CA).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of CA$0.49 to mean target of N/A, Based on analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
%
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 23, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 346.91% | N/A 273.92% | N/A 94.41% | N/A 65.00% | N/A 37.36% | |||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 587.50% | N/A 258.86% | N/A 411.52% | N/A 106.54% | N/A 71.79% | N/A 40.14% | |
| EBIT YoY % growth | -2.009M | -5.206M -159.13% | -3.579M 31.25% | N/A -134.15% | N/A 587.50% | N/A 258.86% | N/A 411.52% | N/A 106.54% | N/A 71.79% | N/A 40.14% | ||
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A -9.12% | N/A 574.77% | N/A 255.10% | N/A 412.43% | N/A 106.50% | N/A 71.89% | N/A 40.15% |
All data in CAD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in CAD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
173.22%
EPS Next 5 Year
187.57%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
169.14%
EBIT Next 5 Year
184.63%